MICHAEL N. MCCARTY LAW OFFICE PLLC for AMERICAN MEDICAL TECHNOLOGISTS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Legislation affecting payment for clinical laboratory diagnostic tests, including but not limited to COVID-19 tests; Promote legislative amendments to section 216 of the Protecting Access to Medicare Act of 2014 (PAMA) to implement Medicare Payment Advisory Commission (MedPAC) recommendations to Congress on prospective improvements to methodologies for market pricing of the Medicare Clinical Laboratory Fee Schedule; support legislation to delay fee schedule reductions and data reporting under PAMA sec. 216.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL N MCCARTY | — |
Medical/Disease Research/Clinical Labs MED
Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL N MCCARTY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.